Annual report pursuant to Section 13 and 15(d)

1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.21.2
1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Apr. 02, 2019
Noncontrolling interests   $ (136,914) $ (132,124)  
Increase (decrease) in noncontrolling interest   (4,790)    
Cash equivalents   0 0  
Cash balances over insured amount   9,712,000    
Asset impairment charges   $ 0 $ 0  
Shares considered antidilutive   2,836,062 2,072,492  
Amortization of deferred financing costs   $ 0 $ 0  
Revenue recognized   659,104 650,187  
Research and development expenses   2,072,000 927,000  
Restricted cash   46,726 0  
Revenues   659,104 650,187  
Lease liabilities       $ 228,694
Right-of-use lease assets   40,363 136,426 $ 228,694
National Institute of Health [Member]        
Revenue recognized   659,104 650,187  
National Institute of Health [Member] | Melanoma Cancer Contract Phase 2 [Member]        
Revenue recognized   436,427    
Revenue recorded, previously accrued $ 117,849 318,578    
Deferred revenue   114,849    
National Institute of Health [Member] | Breast Cancer Grant [Member]        
Revenue recognized   $ 188,444 $ 34,233  
ESI [Member]        
Equity ownership percentage   80.00% 80.00%  
Noncontrolling interests   $ (136,914) $ (132,124)